Home To Our Shareholders Letter from Belén Garijo The Executive Board Our Shares In figures Management Report Fundamental Information about the Group The Group Our response to Covid-19 Life Science Healthcare Electronics Strategy Strategy Fundamentals Enterprise strategy Business Strategies Sustainability Strategy Strategic finance and dividend policy Internal Management System Key performance indicators Investments and value management Capital market-related parameters Other relevant/non-financialperformance measures Research and Development Life Science Healthcare Electronics Report on Economic Position Macroeconomic Environment Review Forecast against Business Developments Course of Business and Economic Position Group Life Science Healthcare Electronics Corporate and Other Report on Risks and Opportunities Business-related risks and opportunities Financial risks and opportunities Tax risks Legal risks Human resources risks Information technology risks Environmental, climate-related, and safety risks and opportunities Other risks Management assessment Report on Expected Developments Report in accordance with section 315a of the German Commercial Code (HGB) Non-Financial Statement Environmental matters Environmental stewardship Climate action Plant, process and transport safety Chemical product safety Employee-related matters Attracting and retaining talent Diversity, equity and inclusion Health and safety Social matters and respect for human rights Responsible supply chain Human rights Patient safety Product-related crime Prices of medicines Clinical studies Bioethics Digital ethics Data protection and privacy Anti-corruption and anti-bribery Compliance management Interactions with health systems Other topics Sustainable innovation & technology Reporting in accordance with the EU Taxonomy Regulation Compensation Report Review of the 2021 fiscal year Determining the compensation of the Executive Board Overview of the structure of the compensation system Executive Board compensation for 2021 Long-Term Incentive Plan (LTIP) Individual disclosure of the compensation of the Executive Board Compensation for the Supervisory Board members in fiscal year 2021 Comparative presentation of compensation and earnings development Additional Information in accordance with the German Commercial Code (HGB) Corporate Governance Capital Structure and Corporate Bodies Statement on Corporate Governance Corporate governance practices Procedures of the Executive Board, Supervisory Board, Board of Partners, and its Committees Promote women in management positions Diversity policy Report of the Supervisory Board Objectives of the Supervisory Board Consolidated Financial Statements Income Statement Statement of Comprehensive Income Balance Sheet Cash Flow Statement Statement of Changes in Net Equity Notes General Disclosures 1. Company information 2. Reporting principles 3. Discretionary decisions and sources of estimation uncertainty 4. Subsequent events Group Structure 5. Changes in the scope of consolidation 6. Acquisitions and divestments 7. Collaboration and licensing agreements Operating Activities 8. Segment Reporting 9. Net sales 10. Cost of sales 11. Marketing and selling expenses 12. Research and development costs 13. Other operating income 14. Other operating expenses 15. Income tax 16. Operating cash flow 17. Earnings per share Operating Assets, Liabilities, and Contingent Liabilities 18. Goodwill 19. Other intangible assets 20. Property, plant, and equipment 21. Leasing 22. Other non-financial assets 23. Cash flow from investing activities 24. Inventories 25. Trade and other receivables 26. Contract assets 27. Other provisions 28. Contingent liabilities 29. Other non-financial liabilities 30. Trade and other payables Employees 31. Number of employees 32. Personnel expenses 33. Provisions for employee benefits Capital Structure, Investments, and Financing Activities 34. Equity 35. Cash and cash equivalents 36. Other financial assets 37. Financial debt/Capital management 38. Other financial liabilities 39. Derivative financial instruments 40. Finance income and expenses/Net gains and losses from financial instruments 41. Net cash flows from financing activities 42. Management of financial risks 43. Information on fair value measurement 44. Other financial obligations Other Disclosures 45. Related party disclosures 46. Executive Board and Supervisory Board compensation 47. Auditor's fees Scope of Consolidation 48. List of shareholdings Other Information Responsibility Statement Reproduction of the Independent Auditor's Report Business Development 2017 – 2021 Financial Calendar